Tablets lower agitation in patients with dementia

Researchers from the McLean Hospital, have found that using tablets is both a safe and effective treatment for agitated patients with dementia.

"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility," said Vahia. "Our preliminary results are a first step in developing much-needed empirical data for clinicians and caregivers on how to use technology such as tablets as tools to enhance care and also for app developers working to serve the technologic needs of this population."

The study published in The American Journal of Geriatric Psychiatry adds to research on art, music and other therapies in reducing the symptoms of dementia without the need for medication. By using tablets, providers and patients gain from the flexibility of these devices as well as their capabilities to provide endless entertainment and data feedback.

"The biggest advantage is versatility," said Vahia. "We know that art therapy can work, and music therapy can work. The tablet, however, gives you the option of switching from one app to another easily, modifying the therapy seamlessly to suit the individual. You don't need to invest in new equipment or infrastructure."

Tablets were loaded with 70 free apps from the Apple iTunes store, which ranged from pictures of puppies to Sudoku puzzles, and distributed to 36 patients when agitated. Providers were then able to document the frequency, duration and app usage history in order to rate how these apps improved patient’s agitation.

Results showed that, with supervision and training, the rate of engagement was nearly 100 percent, regardless of dementia severity. The study also found those with more severe the dementia used less complicated apps. Age negatively affected the frequency and duration of tablet use. However, tablets were able to significantly reduce symptoms of agitation in patients with mild forms of dementia.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup